公开(公告)号：US20250066504A1

公开(公告)日：2025-02-27

申请号：US18847463

申请日：2023-03-16

Applicant: CANARIABIO INC.

Inventor： Christopher F. NICODEMUS ,  Ragupathy MADIYALAKAN

IPC: C07K16/30 ,  A61K31/454 ,  A61K39/00

Abstract: The present document describes a method for improving likelihood of survival in a stage III-IV ovarian cancer patient. The method comprises at least steps of (a) administering daily to a stage III-IV ovarian cancer patient a therapeutically effective dose of Niraparib, for at least 12 weeks; and (b) administering to the patient a therapeutically effective dose of monoclonal antibody mAb-B43.13 during week 1, week 4, week 7, week 12 and week 20 of a treatment period, wherein (a) is performed first and step (b) is performed second, to increase the patient's likelihood of survival in comparison with a control patient who has been diagnosed with stage III-IV ovarian cancer and has received standard of care chemotherapy treatment.